

https://www.globenewswire.com//news-release/2023/09/25/2748334/0/en/Press-Release-Once-weekly-ALTUVIIIO-approved-in-Japan-as-a-new-class-of-factor-VIII-therapy-for-hemophilia-A.html
https://www.globenewswire.com//news-release/2023/09/22/2747747/0/en/Press-Release-Availability-of-the-Q3-2023-Memorandum-for-modelling-purposes.html
https://www.fiercepharma.com/pharma/sanofi-steadfast-slimming-down-offloads-11-central-nervous-system-meds-pharmanovia
https://www.globenewswire.com//news-release/2023/09/19/2745307/0/en/Press-Release-Sanofi-supporting-vulnerable-communities-as-part-of-commitment-to-social-impact-and-fight-against-climate-change.html
https://www.globenewswire.com//news-release/2023/09/14/2743056/0/en/First-Wave-BioPharma-Announces-Exclusive-Global-License-Agreement-for-Capeserod-from-Sanofi.html
https://www.globenewswire.com//news-release/2023/09/11/2741125/0/en/Sanofi-Information-concerning-the-total-number-of-voting-rights-and-shares-August-2023.html
https://www.sanofi.com/en/media-room/press-releases/2023/2023-09-05-14-35-45-2737579
https://www.reuters.com/business/healthcare-pharmaceuticals/us-senators-push-drugmakers-details-low-cost-insulin-programs-2023-08-31/
https://www.biopharmadive.com/news/sanofi-houman-ashrafian-research-development-john-reed/692448/